Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 4

Sponsor Class

INDUSTRY 226OTHER 201NIH 12NETWORK 11OTHER_GOV 5UNKNOWN 4

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 3Hormone Receptor Positive Advanced Breast Cancer 1

Interventions

Paclitaxel 20Capecitabine 18S 1 (combination) 17Cisplatin 15Oxaliplatin 11apatinib 8Radiotherapy, Intensity-Modulated 8Epirubicin 8Docetaxel 8Carboplatin 8Radiotherapy 7Irinotecan 7titanium silicide 6sintilimab 6pyrotinib 6nimotuzumab 6anlotinib 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6nedaplatin 5camrelizumab 5Temozolomide 5Etoposide 5Drug Therapy 5Bevacizumab 5nabiximols 4Vinorelbine 4Trastuzumab 4Radiation Dose Hypofractionation 4Radiation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
UNKNOWN × Fulvestrant × Clear all
NCT05000736 2022-04-29

CAPACITY

ChineseAMS

Unknown
600 enrolled
Breast

Hormone Receptor Positive Advanced Breast Cancer

NCT04289974 2020-02-28

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

ChineseAMS

Unknown
100 enrolled
Breast

Breast Neoplasms

NCT04033172 2019-07-25

Pyrotinib

ChineseAMS

Phase 2 Unknown
40 enrolled
Breast

Breast Neoplasms

NCT02646735 2017-01-02

FRIEND

ChineseAMS

Phase 2 Unknown
148 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡